Investor Relations
Capital partners for pharma-grade longevity.
Founded in 2022, Nanyang Biologics is building a vertically integrated AI drug discovery platform — from a 2B+ compound library to clinical assets in metabolic health, inflammation, and oncology.
Key metrics
- Compound library
- 2B+
- Molecules generated
- 10M+
- Hit-rate uplift
- 64x
- Predictive accuracy
- 44.83%
Virtually screenable molecules accessible through our AI pipeline.
Novel candidates produced by our generative discovery models.
Measured improvement over conventional high-throughput screening.
Top-line model performance reported in our IEEE DTIGN paper.
Company milestones
2022
Founding
Nanyang Biologics is incorporated in Singapore.
2024
DTIGN publication
Drug-Target Interaction Graph Network published in IEEE.
2025
NeurIPS 2025
Research accepted at NeurIPS 2025.
2026
NVIDIA GTC 2026
Featured at NVIDIA GTC 2026.
Leadership
TODO(content) — Founder & CEO
Founder & Chief Executive Officer
TODO(content): two-line bio covering scientific background, prior company affiliations, and key publications.
TODO(content) — Chief Scientific Officer
Chief Scientific Officer
TODO(content): bio summarising drug discovery experience and therapeutic areas.
TODO(content) — Chief Technology Officer
Chief Technology Officer
TODO(content): bio covering ML/AI background and prior systems built.
TODO(content) — Head of Clinical
Head of Clinical Development
TODO(content): bio covering clinical trial leadership.
Press kit
Company fact sheet, leadership headshots, brand assets, and the DTIGN paper.
Investor contact
We'll respond within 2 business days with a data-room access form.
Step 2 of 3